TCT-127 The Impact of Later Generation Thoracic Aortic Stent Grafts as Demonstrated in the VALOR II Trial
Harbor- UCLA Medical Center, Torrance, CA, 5 Albany Medical Center, Albany, NY, 6 Cleveland Clinic Foundation, Cleveland, OH, 7 Inova Fairfax Hospital, Fairfax, VA, 8 Hospital of the University of Pennsylvania, Philadelphia, PA Background: Improvements in technique and devices promise improved outcomes following endovascular repair of aneurysms of the descending thoracic aortic. This mid-term report provides an update to the VALOR II trial results. Methods: VALOR II is a prospective, multicenter, observational study of endovascular treatment with the Valiant thoracic stent graft (Medtronic Endovascular Therapies, Santa Rosa, Calif) in patients with descending thoracic aortic aneurysms (TAA) of degenerative etiology. Results: VALOR II enrolled 160 patients between December 2006 to September 2009 and 1-year results have been previously reported. In this update, follow-up was available on 72% of patients through 3 years. One additional aneurysm-related death occurred after 1 year. One conversion to surgery was performed at 3 years in a patient who had continued aneurysm expansion in the absence of any observable endoleak. Seven secondary stent graft procedures were performed in 6 patients; 1 in the first 30 days, 3 after 1 year and 3 after 2 years. Freedom from secondary stent graft procedures was 94.9% at 3 years (95% CI: 88.8%-97.7%), which compared favorably with the earlier VALOR trial (85.1% at 3 years; 95% CI: 78.5%-89.8%), a study of the Talent thoracic stent graft with similar objectives and inclusion criteria. There was no type I or III endoleak reported at 2 or 3 years. Results: Mean length of ICU was halved with REVAR VS OR (PϽ0.008). Blood product requirements were 60% less in REVAR (PϽ0.0001). The Risk of ARDS and cardiac events were doubled if OR were performed .However there were no statistical significance in acute renal injury. Mean length of hospital stay was 7ϩ/Ϫ3 days for REVAR , and 12ϩ/Ϫ6 for OR (PϽ0.042).Thirty day mortality was 16% for REVAR vs 32% for OR ( PϽ0.001). Total Emergency mortality rate decreased from 64% to 28.2%. we attributed the Low Mortality Rate of 16%for REVAR Vs 32%in OR was due to introduction of an REVAR Programme which constitutes screening for prevention with early intervention and REVAR for rupture which has an absolute perioperative mortality reduction of 49% over OR. 5 years Survival of Patients with RAAA were 75% REVAR vs. 60% OR (pϭ0.0205). During 20th century 95% of all AAA were done surgically. However during 21st century 80% of AAA is done endovascularly. Mean Annual number of OR dropped (PϽ0.845) however Mean Annual number of EVARs had rocketed (PϽ0.006) . Overall number of AAA repairs has increased by 65% over twelve year's period but the absolute number of RAAA had declined by 24%. Conclusions: Para-Millennium and Contemporary Trends in AAA Management had shown Increased in Elective EVAR which increased the mortality advantage in favour of REVAR and it should be the Gold standard for RAAA. 
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